Novo Nordisk A/S (NYSE:NVO) was the target of unusually large options trading on Thursday. Investors acquired 5,495 put options on the stock. This represents an increase of 3,797% compared to the average daily volume of 141 put options.

A number of institutional investors and hedge funds have recently modified their holdings of NVO. Advisors Preferred LLC acquired a new stake in shares of Novo Nordisk A/S in the second quarter valued at about $26,000. TCG Advisors LP acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $27,000. Valeo Financial Advisors LLC increased its stake in shares of Novo Nordisk A/S by 510.7% in the second quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock valued at $32,000 after buying an additional 526 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $41,000. Finally, Bremer Bank National Association acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $41,000. 7.36% of the stock is owned by institutional investors and hedge funds.

NVO traded down $0.17 on Friday, reaching $49.50. The stock had a trading volume of 1,560,200 shares, compared to its average volume of 1,428,443. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $53.55. The firm has a 50-day moving average of $50.81 and a 200-day moving average of $49.93. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $117.45 billion, a price-to-earnings ratio of 19.64, a price-to-earnings-growth ratio of 2.11 and a beta of 0.57.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Friday, August 9th. The company reported $0.61 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.61. Novo Nordisk A/S had a return on equity of 75.16% and a net margin of 32.16%. The business had revenue of $4.52 billion during the quarter, compared to analysts’ expectations of $4.41 billion. Sell-side analysts anticipate that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.

The company also recently announced a Semi-Annual dividend, which was paid on Tuesday, August 27th. Shareholders of record on Monday, August 19th were issued a $0.318 dividend. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s payout ratio is presently 25.40%.

Several brokerages recently weighed in on NVO. ValuEngine downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a research report on Monday, July 15th. UBS Group reaffirmed a “buy” rating and issued a $355.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Jefferies Financial Group cut Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a report on Friday, August 30th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $400.00 target price (up previously from $355.00) on shares of Novo Nordisk A/S in a report on Friday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $159.65.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: What is a portfolio manager?

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.